← All diseases
Cancer
Multiple myeloma
Do you want to receive a message when there is new research about Multiple myeloma? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication appears one sentence explaining what was investigated — and you receive a notification as soon as there is new research about Multiple myeloma. View what Premium costs.
Publications and studies (2178)
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Secondary poor graft function after autologous stem cell transplantation in multiple myeloma: a case-based expert review and successful rescue with secondary autologous stem cell infusion. (2026/12/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. (2026/12/01) ♡
- Pretransplant muscle status as a predictive marker for diarrhea duration and hospital length of stay in patients undergoing hematopoietic stem cell transplantation: a prospective cohort analysis. (2026/09/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy. (2026/09/01) ♡
- Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis. (2026/09/01) ♡
- DNA Replication Stress-Induced Transcriptome of Human Burkitt's Lymphoma Identifies Reciprocal Regulation Between MBD1 and BCL6 During Germinal Center-Derived B-Lymphomagenesis. (2026/09/01) ♡
- Prospective Head-To-Head Comparison of a 10-Color Single-Tube Flow Cytometry and EuroFlow Next-Generation Flow in Multiple Myeloma Minimal Residual Disease. (2026/08/11) ♡
- Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment. (2026/08/10) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fluorodeoxyglucose PET/CT in Nonlymphoma Hematolymphoid Disorders. (2026/08/10) ♡
- Anticancer Activity of Liposomes Prepared Solely From Cardiolipin. (2026/08/10) ♡
- Doubts have been raisediIn this research, a concern about its accuracy was formally published. It has not been retracted, but there is ongoing doubt about its reliability. Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. (2026/08/10) ♡
- Corneal Epithelial Thickness Alterations in Multiple Myeloma Patients Treated with Belantamab Mafodotin. (2026/08/10) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Effect of Polyphenols Derived from Medicinal Plants on Multiple Myeloma via Modulating Bone Marrow Microenvironment. (2026/08/10) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clonal dynamics on the road to hematological malignancy (MBL, MGUS, CH). (2026/08/09) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Monoclonal Gammopathy of Thrombotic Significance. (2026/08/09) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Prophylactic tocilizumab for bispecific T-cell engagers in multiple myeloma: current evidence and clinical considerations for mitigating cytokine release syndrome. (2026/08/07) ♡
- SKY92 Identifies High-Risk Newly Diagnosed Multiple Myeloma With Inferior Progression-Free Survival and Implicates NUF2 as a Candidate Driver. (2026/08/07) ♡
- Kidney Injury Associated with Monoclonal Gammopathy: A Nephrologist's Perspective. (2026/08/07) ♡
- The HALP score is a novel prognostic biomarker in multiple myeloma: A retrospective cohort study of 450 patients. (2026/08/07) ♡
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients. (2026/08/07) ♡
- Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. (2026/08/06) ♡
- Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients. (2026/08/06) ♡
- Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs. (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma? (2026/08/05) ♡
- Mechanistic modeling of time-dependent antibody clearance in multiple myeloma: A physiologically based pharmacokinetic model of isatuximab. (2026/08/05) ♡
- From Bone Pain to Severe Renal Symptoms: The Journey of a Patient With Multiple Myeloma and Brucellosis (Case Report). (2026/08/05) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Hematological Malignancies: A Narrative Review of Current and Emerging Evidence. (2026/08/05) ♡
- tRNA-derived fragment tRF-17-8SPOL52 induces resistance to bortezomib in multiple myeloma via autophagy activation. (2026/08/05) ♡
- Retraction: A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity. (2026/08/04) ♡
- Retraction: Mammalian Target of Rapamycin Inhibitors Activate the AKT Kinase in Multiple Myeloma Cells by Up-regulating the Insulin-like Growth Factor Receptor/Insulin Receptor Substrate-1/Phosphatidylinositol 3-Kinase Cascade. (2026/08/04) ♡
- Adaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethics. (2026/08/04) ♡
- Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare. (2026/08/04) ♡
- Increased Risk of Infections and Mortality Following Fractures in Multiple Myeloma: A Nationwide Population-Based Retrospective Cohort Study. (2026/08/04) ♡
- Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences. (2026/08/04) ♡
- Laboratory characteristics of direct antiglobulin test-positive anemia in patients with newly diagnosed multiple myeloma. (2026/08/04) ♡
- A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data. (2026/08/04) ♡
- Automated B-cell and plasma cell identification using unsupervised clustering by FlowSOM and an excel-based classification model. (2026/08/03) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence. (2026/08/03) ♡
- Monoclonal gammopathy of clinical significance: a guide for nephrologists. (2026/08/03) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Editorial Note: Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. (2026/08/03) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. O-GlcNAc transferase as an oncogenic regulator in hematologic malignancies: Mechanisms, disease contexts, and therapeutic perspectives. (2026/08/03) ♡
- Cement Use in Bipolar Hemiarthroplasty and Its Association With Cancer Risk. (2026/08/03) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Infection Prevention and Management in Patients Living With Multiple Myeloma. (2026/08/03) ♡
- DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma. (2026/08/03) ♡
- High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients. (2026/08/02) ♡
- Rare Nodular Hepatosplenic Involvement in Multiple Myeloma: FDG PET/CT and MRI Correlation with Treatment Response. (2026/08/01) ♡
- Geriatric nutritional risk index for the prediction of venous thrombotic events in multiple myeloma. (2026/08/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Centrifugation-based plasma exchange overcomes blood flow restriction to rescue hyperviscosity syndrome in IgM-κ multiple myeloma: a case report. (2026/08/01) ♡
- Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia. (2026/08/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Plasma Exchange in Myeloma-Associated Acute Kidney Injury: A Multicenter Propensity-Matched Cohort Study. (2026/08/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.